Explore
Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers
0 Ungluers have
Faved this Work
Login to Fave
The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody–Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each paper was written by leading active research groups in their fields both from academia and industry. The book should be of interest to those scientists and researchers who develop or use biologics, biotherapeutics, biosimilars and biobetters in cancer treatment.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 65 times via unglue.it ebook links.
- 65 - pdf (CC BY) at Unglue.it.
Keywords
- active-targeting
- acute myeloid leukemia
- ADC
- ADCC
- affibody
- Ang-2
- Angiogenesis
- anti-acetylcholine receptor (AChR) antibody
- anti-PD-1 monoclonal antibodies
- antiangiogenic therapy
- antibody
- antibody products
- antibody-drug conjugate
- antibody-drug conjugates
- B cell
- B cell maturation antigens (BCMAs)
- biomarkers
- bispecific T cell engagers (BiTEs®)
- Cancer
- cancer therapy
- canine B-cell lymphoma
- CD123
- CD133
- cell penetrating peptide
- checkpoint inhibitors 1
- colorectal cancer
- combination therapy
- dermatooncology
- DLA-DR
- DM1
- drug conjugates
- drug optimization 4
- Economics, finance, business & management
- ELISA
- gold nanoparticles
- hepatic uptake
- HER2-positive breast cancer
- HIV-1 TAT
- HLA-DR
- IL3RA
- immune checkpoint blockade
- immune checkpoints
- immune-checkpoint inhibitors
- immune-related adverse events (irAEs)
- Immunotherapy
- in vivo imaging
- Industry & industrial studies
- kinesin spindle protein inhibitor
- LDH
- Manufacturing industries
- medicine
- metastatic disease
- methotrexate
- MMAE
- monoclonal antibodies
- monoclonal antibodies (mAbs)
- Monoclonal antibody
- multiple myeloma (MM)
- myasthenia gravis (MG)
- neoadjuvant and adjuvant therapy
- neovascularization
- Nivolumab
- NK cells
- non-small-cell lung cancer (NSCLC)
- NSCLC
- passive immunotherapy
- Pharmaceutical industries
- Pharmacogenetics
- pharmacokinetics
- pharmacokinetics 3
- programmed cell death ligand 1 (PD-L1)
- prominin-1
- protein structure 2
- radio- and chemotherapy
- radioimmunotherapy
- T cell
- targeted delivery
- targeted therapy
- Tetraspanins
- trastuzumab
- Tspan8
- tumor immunity
- Tumor microenvironment
- valine-citrulline
- VEGF-A
Links
DOI: 10.3390/books978-3-0365-2686-7Editions